Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of choice to consolidate remission in patients with poor-risk acute myeloid leukemia (AML). With increasing alternative donors available, the preferred donor or stem cell source is debated. We set out to study outcom...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Versluis, Jurjen, Labopin, Myriam, Ruggeri, Annalisa, Socie, Gerard, Wu, Depei, Volin, Liisa, Blaise, Didier, Milpied, Noel, Craddock, Charles, Yakoub-Agha, Ibrahim, Maertens, Johan, Ljungman, Per, Huynh, Anne, Michallet, Mauricette, Deconinck, Eric, Chevallier, Patrice, Passweg, Jakob, Ciceri, Fabio, Mohty, Mohamad, Cornelissen, Jan J., Nagler, Arnon
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2017
Assuntos:
Transplantation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5738980/
https://ncbi.nlm.nih.gov/pubmed/29296964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016002386
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares